[{"id":"52d33ddf-12db-4781-8289-d23be5e18186","acronym":"CYTB323A12101","url":"https://clinicaltrials.gov/study/NCT03960840","created_at":"2021-01-18T19:29:26.737Z","updated_at":"2024-07-02T16:35:06.077Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL","source_id_and_acronym":"NCT03960840 - CYTB323A12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-05-03"}]